Latent membrane protein 1 and Latent membrane protein 2 (LMP1/LMP2)

Latent membrane protein 1 (LMP1) and Latent membrane protein 2 (LMP2) are essential oncogenic proteins encoded by the Epstein-Barr virus (EBV) that play critical roles in maintaining viral latency and driving cellular transformation (PMID: 30633411). LMP1 functions as a constitutive mimic of the CD40 receptor, activating signaling pathways such as NF-κB and PI3K to promote cell survival and proliferation, while LMP2 (specifically the LMP2A isoform) mimics a constitutively active B-cell receptor to provide essential survival signals to B cells (PMID: 25633481). These proteins are consistently expressed in EBV-associated malignancies, including nasopharyngeal carcinoma and Hodgkin lymphoma, making them primary targets for immunotherapy. Therapeutic strategies focus on T-cell receptor (TCR) recognition, where engineered T cells or endogenous cytotoxic T lymphocytes are directed to recognize specific LMP-derived peptides presented by MHC molecules (PMID: 31515463). This approach allows for the selective destruction of EBV-positive tumor cells while minimizing damage to healthy, non-infected tissues (PMID: 33063341).

Other names

EBV-LMP1EBV-LMP2Epstein-Barr virus latent membrane proteinsBNLF1BKRF1BNRF1LMP2ALMP2B

T-cell receptor (TCR) recognition of specific LMP1 or LMP2 peptide fragments presented by Major Histocompatibility Complex (MHC) molecules on the surface of EBV-infected cells, triggering T-cell mediated cytotoxicity.